ClearPoint Neuro, Inc. (CLPT) stock
CLPTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3012% above fair value
$7.86−0.44 (-5.30%)
Close on Nov 17, 2026Market cap $251.95MP/E –Yield –
ClearPoint Neuro price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
ClearPoint Neuro's price to sales ratio was 6.6× on Nov 11, 2026, against 12.0× a year earlier. Over the last 5 years it ranged from 5.6× to 19.6×, with a median of 10.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 6.6× | −4.7 |
| 2025 | Dec 31, 2025 | 11.3× | −2.6 |
| 2024 | Dec 31, 2024 | 13.9× | +6.5 |
| 2023 | Dec 29, 2023 | 7.5× | −3.1 |
| 2022 | Dec 30, 2022 | 10.6× | −5.7 |
| 2021 | Dec 31, 2021 | 16.3× | −4.2 |
| 2020 | Dec 31, 2020 | 20.5× | +13.5 |
| 2019 | Dec 31, 2019 | 7.0× | +4.4 |
| 2018 | Dec 31, 2018 | 2.6× | −1.3 |
| 2017 | Dec 29, 2017 | 3.9× | +1.7 |
| 2016 | Dec 30, 2016 | 2.2× | −4.9 |
| 2015 | Dec 31, 2015 | 7.0× | −5.8 |
| 2014 | Dec 31, 2014 | 12.8× | −5.6 |
| 2013 | Dec 31, 2013 | 18.4× | −0.7 |
| 2012 | Dec 31, 2012 | 19.0× | – |
See a number that looks wrong?